Standard BioTools to sell mass cytometry business to Multiplex Bio for up to $10 million

Closing is targeted by the end of 2026, substantially concurrent with the Treeline transaction, and is subject to stockholder approval and customary conditions.

Standard BioTools will provide a working capital loan of up to $10 million at closing.

CyTOF and Hyperion product lines will continue under the Standard BioTools brand, with most of the Mass Cytometry team transferring.

Standard BioTools agreed to sell its Mass Cytometry business to Multiplex Bio as it advances a planned merger with Treeline.

The deal is valued at up to $10 million, including a seller's note from Multiplex Bio and a potential milestone payment.